A growing portfolio
of approved therapies
Mirum’s portfolio of approved therapies reflects our commitment to advancing care in serious and often overlooked rare diseases.
Each medicine reflects our dedication to the patients and caregivers who inspire our work, bringing important treatment options and supporting care across the communities we serve.
Please visit the specific product brand page for important safety information, labeling considerations, and warnings that relate to each product.
Patient support & access programs
Mirum Access Plus (MAP) – U.S.
Designed to help patients and families start and stay on Mirum medicines, this program connects patients and families with MAP experts who can help educate on the journey, from treatment access to financial support.
Embrace Patient Support Program for LIVMARLI (maralixibat) – Canada
For more information about the Embrace Patient Support Program for access in Canada, call 1-833-505-1242 or email support@mirumembrace.com.
Expanded access forLIVMARLI® (MARALIXIBAT)
Mirum’s Expanded Access Program (EAP) offers access to LIVMARLI for eligible patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).
- Physicians in Canada and the U.S. who are interested in the ALGS EAP should contact mirumalgs@clinigengroup.com
- Physicians in Canada and the U.S. who are interested in the PFIC EAP should contact mirumPFIC@clinigengroup.com
- Physicians outside of Canada and the U.S. who are interested in the PFIC or ALGS EAP should contact medicineaccess@clinigengroup.com
- To learn more about Mirum’s open clinical trials, please visit www.clinicaltrials.gov
A pipeline with
purpose inrare disease
Explore our pipeline of therapies aimed at addressing
unmet needs in rare diseases.
